DISC held its 2025 ASH Management Call on December 7, 2025, revealing significant insights into its pipeline.
Key updates include positive results on hemoglobin and transfusion burden in anemia of MF.
Investigational agents, including Bitopertin and DISC-0974, show promising developments in clinical trials.
Clinical Progress
DISC-0974 shows favorable data in treating Anemia of MF.
Pipeline Expansion
Plans to explore therapeutic potential of DISC-0974 in other inflammatory anemias.
Commercial Readiness
Preparations for the potential commercial launch of Bitopertin are underway.
- The disclosed updates show consistent and substantial reductions in hepcidin levels and increase in iron.
- These developments indicate positive and durable benefits for patients with anemia, reducing transfusion dependency.
DISC's progress in its pipeline and promising clinical developments position the company for future growth and potential market success.